Press Releases from PNS Pharma (125 total)
US Colorectal Cancer Drug Pipeline Analysis
Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die…
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds…
Global Cancer Monoclonal Antibodies Pipeline Analysis
In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies.
In recent years the popularity…
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the…
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future.
There has been a…
US Cancer Vaccine Pipeline Analysis
Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Merck’s Gardasil, a Prophylactic cancer vaccine,…
Europe Alzheimer’s Drug Pipeline Analysis
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure…
Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that…
Japan Cancer Drug Pipeline Analysis
Japan is a significant market for cancer and its related drugs in the Asia-Pacific region. Improved access to healthcare and an increased level of awareness about cancer and the options for its treatment have been major drivers for a rise in the research activities in this country.
With the strong continued support from the government, the Japanese cancer market is expected to grow rapidly in the future years. The government has…
US Skin Cancer Drug Pipeline Analysis
The market for skin cancer in the US is expected to grow significantly owing to reasons like increasing number of patients and entry of new therapies which are in the pipeline. Additionally, the organic growth of key marketed drugs is also another major factor driving the growth in the US market. Of the different types of skin cancers in the US, Melanoma is the most common. Though this segment accounts…
Europe Lung Cancer Drug Pipeline Analysis
The most common type of cancer in terms of incidence and mortality rate is Lung cancer. Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which in turn leads to the formation of tumor. There are two main types of lung cancer; small cell lung cancer which accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts…
Europe Orphan Drug Pipeline Analysis 2014
Rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. The term “orphan” was associated with these drugs in order to reflect the lack of interest by pharma companies. In the European Union, orphan drugs are known as orphan medicinal products. Many treatments which are commercially available in today’s world lack the ability to address most…
Global Vaccine Market Pipeline Analysis
The global vaccine market is characterized into human and animal vaccines. The segment of human vaccines is further sub-divided into four groups namely, pediatrics, adolescents, adults and elderly. Though the vaccines segment forms a very small portion of the global pharmaceutical drug sales(2-3%), the growth rate in this market has been extraordinary. This segment has grown at a high rate of 10-15% annually as compared to the overall pharmaceutical industry…
Global Peptide Therapeutics Market & Pipeline Insight
With a very significant role in modulating cell functions, peptides are used in many physiological and pathological processes. The peptide drugs are of late being increasingly used in treatment of certain specific human diseases, which has increased the demand in this market.
Previously peptide drugs were not very popular. However, in recent years, as the total number of small molecule-based drugs in the clinical trials and approved drugs for the market…
Crohn’s Disease Drug Market and Pipeline Analysis
Under the umbrella of inflammatory bowel diseases, Crohn’s disease and ulcerative colitis are two most common disorders. Though both these disorders have similar symptoms, the difference arises in the areas affected in the gastrointestinal tract (GI tract). The Crohn’s disease in most cases affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from…
Human Papillomavirus Infections Vaccine Pipeline Analysis
Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as…
Cancer Cytokines Therapy Pipeline Analysis
Cytokines, a major group in the protein therapeutics umbrella, are known to be soluble extracellular proteins or glycoproteins which are crucial intercellular regulators, having the capacity to mobilize the cells which are engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. These proteins are being used mostly for cancer patients due to…
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could…
Cervical Cancer Drug Market & Pipeline Insight
`Cervical cancer is the third and fourth most common cause of cancer incidence and mortality among women across the world. Though there has been a decline in cervical cancer mortality rates in the previous few years, owing to early detection and intervention, challenges like over-diagnosis and over-treatment of the disease continue to remain. As per the World Health Organization (WHO), more than half a million new cases are diagnosed annually…
Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide…
US Orphan Drug Pipeline Insight 2014
Rare diseases are also known as Orphan diseases. These diseases are generally categorized as chronic, degenerative, and life-threatening in nature. The rare diseases normally include certain cancers, metabolic conditions, diseases of the nervous system and musculoskeletal disorders, which are extremely life-threatening. As per the official definition, rare diseases are classified as those that affect fewer than 200,000 in the US and less than 5 in 10,000 in the EU.
The…
US CNS Disorders Drug Pipeline Insight 2014
The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. In US, the numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the…
Europe Orphan Drug Market & Clinical Trial Insight 2015
The concept of rare diseases and the idea that a special attention needs to be given to this sector has been taking shape in Europe since the 1990s. ever since then the political aspects and initiatives related to orphan medicinal products have been emerging at both the EU level and at the level of member states individually. Many member states in the EU have led the way during the 1990s…
Global Orphan Drug Pipeline & Regulatory Insight 2015
Rare diseases are also known as Orphan diseases. These diseases are generally categorized as chronic, degenerative, life threatening in nature and normally include certain cancers, metabolic conditions, diseases of the nervous system and musculoskeletal disorders. As per the official definition, rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. These two regions form a dominant…
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
Prostate cancer has emerged as a disease with one of the highest incidences and mortality rates in males across the world. This situation has created a large unmet medical demand for better therapeutics by patients suffering from prostate cancer due to modest response generated by presently available therapeutics. Hormone based therapeutics and chemotherapeutics helped in improving the patient’s condition but they have side effects and modest pharmacological benefits reflecting necessity…
Small Molecule Cancer Drug Clinical Pipeline Insight
Oncologists are continuously looking for better therapeutic options to effectively cure and prevent different types of malignancies. Conventionally, surgery and radiation were widely used for cancer treatment but they have modest benefits. Presently, global market consists of several options for cancer treatment which belongs to various classes of molecules. Their utilization in therapeutic regime depends on the patient’s medical condition, pharmacological and financial benefits offered by them during treatment. Out…
Subcutaneous Drug Delivery Market & Pipeline Insight
Subcutaneous sites along with intramuscular and intravenous sites are part of parenteral route of drug entry. Maximum pharmacological benefits of a drug could be achieved by deciding effective route of administration depending upon pharmacodynamic properties of the drug to be used. Subcutaneous route is commonly used for the administration of therapeutics into the body for better drug delivery of lipophilic, proteinecious, small molecule drugs. It is characterized by less vasculature,…
Global Peptide Therapeutics Pipeline Insight 2015
Peptides are small molecules of varying molecular masses that consist of amino acids joined with the help of peptide bonds (CONH2). One end of the molecule consists of carboxyl (COOH2) group while the other end has amino (NH2) group giving rise to polarity. Biologically, they are very important and found to play an important role in various anabolic and catabolic processes. They are essential component of cell signaling pathways, immune…
Global Monoclonal Antibodies Pipeline Insight 2015
Ever since the Nobel Prize was bestowed on the person who invented the technology which enabled the preparation of monoclonal antibodies in 1984, their use has considerably expanded far beyond the scientific realm. Paul Ehrlich framed a hypothesis that a “magic bullet” could be developed with an objective of targeting selective diseases. With the introduction and development of hybridoma technology by Kohler and Milstein, this hypothesis has become a reality.…
Global Peptide Therapeutics Market & Clinical Pipeline Insight 2016
Investigators are looking for different molecular entities that could be used for the development of viable therapeutics with commercial potential. Peptide therapeutics are one such category that has gained significant attention in past years. Several products have been launched in global market for different indications. Significant investments have been made by pharmaceutical companies in research and development (R&D) segment in order to come forth with innovative products. They also serve…
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on…
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
…
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014.
Trastuzumab or…
Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight
“Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially available in India, Japan, Kenya, Czech Republic, Estonia, Germany, China, Slovakia, United Kingdom for the treatment of Type 1 & 2 diabetes mellitus. The patent on Lantus expired in 2014.
Lantus is the brand name…
Remicade (Infliximab) Biosimilar Clinical Trial Insight
“Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Remicade are commercially available in India, Brazil and European countries for the treatment of Ankylosing spondylitis, Crohn's disease and Rheumatoid Arthritis. The…
Agenus-Cancer Drugs Clinical Pipeline Insight
“Agenus-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Agenus. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There is 1 cancer drug by Agenus which are commercially available in the market.
The…
Ajinomoto - Cancer Drugs Clinical Pipeline Insight
“Ajinomoto - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Ajinomoto. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “2” cancer drugs in clinical pipeline. There are 3 cancer drugs by Ajinomoto which are commercially available in the market.
The report includes all the relevant information…
Alnylam Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight
“Alnylam Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Alnylam. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline.
The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps…
Alphamab - Cancer Drugs Clinical Pipeline Insight
“Alphamab - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Alphamab. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “13” cancer drugs in clinical pipeline and majority of them are in preclincal phase.
The report includes all the relevant information with respect to development of cancer…
Antigenics - Cancer Drugs Clinical Pipeline Insight
“Antigenics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Antigenics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline and majority of them are in preclincal phase. There are 2 cancer drugs by Antigenics which are commercially available in the…
Arbutus Biopharma-Cancer Drugs Clinical Pipeline Insight
“Arbutus Biopharma-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Arbutus. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in prclinical phase. There is 1 cancer drug by Arbutus Biopharma which is commercially available in the…
ARAID Pharmaceuticals-Cancer Drugs Clinical Pipeline Insight
“ARAID Pharmaceuticals-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by ARAID Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in preclincal phase. There is 1 cancer drug by ARIAD Pharmaceuticals which is commercially available in…
Arqule-Cancer Drugs Clinical Pipeline Insight
“Arqule-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Arqule. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline.
The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying…
Aurigene Discovery Technologies-Cancer Drugs Clinical Pipeline Insight
“Aurigene Discovery Technologies-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Aurigene Discovery Technologies. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “10” cancer drugs in clinical pipeline and majority of them are in preclinical phase.
The report includes all the relevant information with respect to development of…
BTG - Cancer Drugs Clinical Pipeline Insight
“BTG - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by BTG. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline. There are 4 cancer drugs by BTG which are commercially available in the market.
The report includes all the relevant information…
Cardiff University - Cancer Drugs Clinical Pipeline Insight
“Cardiff University - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Cardiff University. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “12” cancer drugs in clinical pipeline and majority of them are in phase-III.
The report includes all the relevant information with respect to development of cancer…
Celtic Pharma - Cancer Drugs Clinical Pipeline Insight
“Celtic Pharma - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Celtic Pharma. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drug in clinical pipeline.
The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report…
Cephalon-Cancer Drugs Clinical Pipeline Insight
“Cephalon-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Cephaloan. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “13” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 3 cancer drugs by Cephalon which are commercially available in the market.
The…
Curis - Cancer Drugs Clinical Pipeline Insight
“Curis - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Curis. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “7” cancer drugs in clinical pipeline. There is 1 cancer drug by Curis which are commercially available in the market.
The report includes all the relevant information…
Debiopharma - Cancer Drugs Clinical Pipeline Insight
“Debiopharma - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Debiopharma. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “5” cancer drugs in clinical pipeline. There are 2 cancer drugs by Debiopharma which are commercially available in the market.
The report includes all the relevant information…
